Caprock Group’s Travere Therapeutics TVTX Stock Holding History

Caprock Group’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-8,500	Closed	-$232K	–	539
2020 Q4	$232K	Buy	+8,500	New	+$198K	0.03%	403

Other funds holding TVTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Caprock Group's TVTX Position: Q1 2021 in Review

Caprock Group sold out of Travere Therapeutics (TVTX) in Q1 2021, closing a stake of 8,500 shares — an estimated $232K sold.

Caprock Group first reported a position in TVTX in Q4 2020 and held it in 1 quarter. The position peaked at $232K in Q4 2020. 150 funds tracked by Wall St. Rank hold TVTX as of Q1 2021.

Caprock Group reported no remaining Travere Therapeutics position as of Q1 2021 after selling out during the quarter.
Caprock Group sold 8,500 Travere Therapeutics shares in Q1 2021, an estimated $232K.
Caprock Group first reported a position in Travere Therapeutics in Q4 2020 and held it in 1 quarter.
Caprock Group's Travere Therapeutics position peaked at $232K in Q4 2020.
150 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2021.

Based on Caprock Group's 13F filing for Q1 2021, filed 29 Apr 2021.